A Phase IIa, Randomised, Double Blind, Placebo Controlled, Three Way Crossover Study to Assess the Pharmacokinetics of RPL554 Administered to Adult Patients With Cystic Fibrosis
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Ensifentrine (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Verona Pharma
- 26 Oct 2018 According to a Verona Pharma media release, data from the study has been presented at the 2018 North American Cystic Fibrosis Conference.
- 26 Oct 2018 Results presented in a Verona Pharma media release.
- 08 May 2018 According to a Verona Pharma media release, the company Reported positive top-line data from this study